| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-3223(90)90408-T |
| P698 | PubMed publication ID | 2207219 |
| P2093 | author name string | R J Katz | |
| J DeVeaugh-Geiss | |||
| P Landau | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clomipramine | Q58713 |
| obsessive-compulsive disorder | Q178190 | ||
| P304 | page(s) | 401-414 | |
| P577 | publication date | 1990-09-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Clomipramine in obsessive-compulsive disorder | |
| P478 | volume | 28 |
| Q84446951 | A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder |
| Q38353212 | Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature |
| Q27009995 | Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders |
| Q35327098 | Current management of obsessive and phobic states |
| Q37610143 | Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis |
| Q39274236 | Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines. |
| Q53974700 | Methodological issues in the design of clinical studies of new drugs for the treatment of obsessive compulsive disorder. |
| Q36200991 | Minority participation in randomized controlled trials for obsessive-compulsive disorder |
| Q37535918 | Neurobiology of obsessive compulsive disorder--a serotonergic basis of Freudian repression |
| Q88998394 | Obsessive-compulsive disorder in children and adolescents. A review of the literature |
| Q26851461 | Pharmacological treatment of anxiety disorders: current treatments and future directions |
| Q58113540 | Placebo effect in Obsessive-Compulsive Disorder (OCD). Placebo response and placebo responders in OCD: The trend over time |
| Q35073549 | Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study |
| Q41119587 | Psychopharmacology for dermatologic patients |
| Q40877917 | Psychotropic agents in dermatology. |
| Q71812270 | Selective serotonin reuptake inhibitors in obsessive-compulsive disorder |
| Q60727692 | The clinical characteristics of patients with obsessive compulsive disorder: a descriptive study of an Irish sample |
| Q44758781 | WCA recommendations for the long-term treatment of anxiety disorders. |
| Q35651392 | WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. |
| Q22305681 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders |
Search more.